Compare HKPD & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | PFSA |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.9M |
| IPO Year | 2025 | N/A |
| Metric | HKPD | PFSA |
|---|---|---|
| Price | $0.80 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.9K | ★ 60.3M |
| Earning Date | 02-23-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,313,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.72 | ★ 122.22 |
| 52 Week Low | $0.68 | $0.07 |
| 52 Week High | $2.76 | $12.76 |
| Indicator | HKPD | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 45.93 |
| Support Level | $0.76 | $0.09 |
| Resistance Level | $0.84 | $0.12 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 65.98 | 39.18 |
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.